Racial/Ethnic Differences in Prenatal Supplement and Medication Use in Low-Risk Pregnant Women

Abstract

Objective This study aimed to describe the overall quantity and type of supplements and medications used during pregnancy in a low-risk cohort and to examine any racial/ethnic differences in intake.

Study Design We used data from 2,164 racially/ethnically diverse, nonobese, and low-risk pregnant women participating without pre-pregnancy chronic conditions in a prospective cohort study at 12 sites across the United States. Medication data were self-reported as free text in enrollment, follow-up visit questionnaires, and abstracted from medical records at delivery. Supplements and medications data were mapped to their active ingredients and categorized into corresponding classes using the Slone Drug Dictionary. The total number and classes of supplements and medications consumed during pregnancy were calculated. Modified Poisson regression models were used to estimate the racial/ethnic differences in supplements and medications intake. All models were adjusted for maternal sociodemographic factors and study site.

Results 98% of women took at least one supplement during pregnancy, with prenatal vitamins/multivitamins being most common. While only 31% reported taking no medications during pregnancy, 23% took one, 18% took two, and 28% took three or more. The percentage of women taking at least one medication during pregnancy was highest among non-Hispanic white women and lowest among Asians (84 vs. 55%, p < 0.001). All racial/ethnic groups reported taking the same top four medication classes including central nervous system agents, gastrointestinal drugs, anti-infective agents, and antihistamines. Compared with non-Hispanic white women, Hispanic (adjusted relative risk [aRR]: 0.84, 95% confidence interval [CI]: 0.71–0.98), and Asian women (aRR: 0.83, 95% CI: 0.70–0.98) were less likely to take central nervous system agents, as well as gastrointestinal drugs (Hispanics aRR: 0.79, 95% CI: 0.66–0.94; Asians aRR = 0.75, 95% CI: 0.63–0.90), and antihistamines (Hispanics aRR: 0.65, 95% CI: 0.47–0.92).

Conclusion Supplement intake was nearly universal. Medication use was also common among this low-risk pregnancy cohort and differed by race/ethnicity.

ClinicalTrials.gov Identifier NCT00912132.

Key Points

• In women without chronic conditions, medication use is common.

• Racial/ethnic differences exist in prenatal medications use.

• Almost all women use supplements during pregnancy.

Keywords

pregnancy - medication intake - vitamins - medication classes - medication prevalence

Note

E.H.Y., S.N.H., R.R., J.G., C.Z., and K.L.G. are U.S. federal government employees.

Publikationsverlauf

Eingereicht: 28. Februar 2020

Angenommen: 25. August 2020

Artikel online veröffentlicht:
08. Oktober 2020

• References

• 1 Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet 2011; 157C [phone]
• 2 Lynch MM, Squiers LB, Kosa KM. et al. Making decisions about medication use during pregnancy: implications for communication strategies. Matern Child Health J 2018; 22 (01) 92-100
• 3 Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol 2015; 39 (07) 512-519
• 4 Branum AM, Bailey R, Singer BJ. Dietary supplement use and folate status during pregnancy in the United States. J Nutr 2013; 143 (04) 486-492
• 5 Lee E, Maneno MK, Smith L. et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf 2006; 15 (08) 537-545
• 6 Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011; 205 (01) 51.e1-51.e8
• 7 Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-the-counter medications during pregnancy. Am J Obstet Gynecol 2005; 193 (3 Pt 1): 771-777
• 8 Palmsten K, Hernández-Díaz S, Chambers CD. et al. The most commonly dispensed prescription medications among pregnant women enrolled in the U.S. medicaid program. Obstet Gynecol 2015; 126 (03) 465-473
• 9 Thorpe PG, Gilboa SM, Hernandez-Diaz S. et al; National Birth Defects Prevention Study. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiol Drug Saf 2013; 22 (09) 1013-1018
• 10 Haas DM, Marsh DJ, Dang DT. et al. Prescription and other medication use in pregnancy. Obstet Gynecol 2018; 131 (05) 789-798
• 11 Sullivan KM, Ford ES, Azrak MF, Mokdad AH. Multivitamin use in pregnant and nonpregnant women: results from the behavioral risk factor surveillance system. Public Health Rep 2009; 124 (03) 384-390
• 12 Riley EH, Fuentes-Afflick E, Jackson RA. et al. Correlates of prescription drug use during pregnancy. J Womens Health (Larchmt) 2005; 14 (05) 401-409
• 13 Buitendijk S, Bracken MB. Medication in early pregnancy: prevalence of use and relationship to maternal characteristics. Am J Obstet Gynecol 1991; 165 (01) 33-40
• 14 Grobman WA, Parker CB, Willinger M. et al; Eunice Kennedy Shriver National Institute of Child Health and Human Development Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (nuMoM2b) Network*. Racial disparities in adverse pregnancy outcomes and psychosocial stress. Obstet Gynecol 2018; 131 (02) 328-335
• 15 Burris HH, Mitchell AA, Werler MM. Periconceptional multivitamin use and infant birth weight disparities. Ann Epidemiol 2010; 20 (03) 233-240
• 16 Hasan R, Olshan AF, Herring AH, Savitz DA, Siega-Riz AM, Hartmann KE. Self-reported vitamin supplementation in early pregnancy and risk of miscarriage. Am J Epidemiol 2009; 169 (11) 1312-1318
• 17 Robbins C, Boulet SL, Morgan I. et al. Disparities in preconception health indicators - behavioral risk factor surveillance system, 2013-2015, and pregnancy risk assessment monitoring system, 2013-2014. MMWR Surveill Summ 2018; 67 (01) 1-16
• 18 Johnston EO, Sharma AJ, Abe K. Association between maternal multivitamin use and preterm birth in 24 states, pregnancy risk assessment monitoring system, 2009-2010. Matern Child Health J 2016; 20 (09) 1825-1834
• 19 Jasti S, Siega-Riz AM, Cogswell ME, Hartzema AG, Bentley ME. Pill count adherence to prenatal multivitamin/mineral supplement use among low-income women. J Nutr 2005; 135 (05) 1093-1101
• 20 Buck Louis GM, Grewal J, Albert PS. et al. Racial/ethnic standards for fetal growth: the NICHD fetal growth studies. Am J Obstet Gynecol 2015; 213 (04) 449.e1-449.e41
• 21 Grewal J, Grantz KL, Zhang C. et al. Cohort profile: NICHD fetal growth studies-singletons and twins. Int J Epidemiol 2018; 47 (01) 25-25l
• 22 Kelley KE, Kelley TP, Kaufman DW, Mitchell AA. The slone drug dictionary: a research driven pharmacoepidemiology tool. Pharmacoepidemiol Drug Saf 2003; 12 (S1): 168-169
• 23 Hall SA, Chiu GR, Kaufman DW. et al. General exposures to prescription medications by race/ethnicity in a population-based sample: results from the Boston Area Community Health Survey. Pharmacoepidemiol Drug Saf 2010; 19 (04) 384-392
• 24 Broussard CS, Rasmussen SA, Reefhuis J. et al; National Birth Defects Prevention Study. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011; 204 (04) 314.e1-314.e11
• 25 Benedum CM, Yazdy MM, Mitchell AA, Werler MM. Impact of periconceptional use of nitrosatable drugs on the risk of neural tube defects. Am J Epidemiol 2015; 182 (08) 675-684
• 26 Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004; 159 (07) 702-706
• 27 Lupattelli A, Spigset O, Twigg MJ. et al. Medication use in pregnancy: a cross-sectional, multinational web-based study. BMJ Open 2014; 4 (02) e004365
• 28 Refuerzo JS, Blackwell SC, Sokol RJ. et al. Use of over-the-counter medications and herbal remedies in pregnancy. Am J Perinatol 2005; 22 (06) 321-324
• 29 Tinker SC, Broussard CS, Frey MT, Gilboa SM. Prevalence of prescription medication use among non-pregnant women of childbearing age and pregnant women in the United States: NHANES, 1999-2006. Matern Child Health J 2015; 19 (05) 1097-1106
• 30 Horne R, Graupner L, Frost S, Weinman J, Wright SM, Hankins M. Medicine in a multi-cultural society: the effect of cultural background on beliefs about medications. Soc Sci Med 2004; 59 (06) 1307-1313
• 31 Bussey-Jones J, Genao I. Impact of culture on health care. J Natl Med Assoc 2003; 95 (08) 732-735
• 32 Admon LK, Winkelman TNA, Moniz MH, Davis MM, Heisler M, Dalton VK. Disparities in chronic conditions among women hospitalized for delivery in the United States, 2005-2014. Obstet Gynecol 2017; 130 (06) 1319-1326
• 33 Thomas SH, Yates LM. Prescribing without evidence - pregnancy. Br J Clin Pharmacol 2012; 74 (04) 691-697
• 34 Navaro M, Vezzosi L, Santagati G, Angelillo IF. Collaborative Working Group. Knowledge, attitudes, and practice regarding medication use in pregnant women in Southern Italy. PLoS One 2018; 13 (06) e0198618
• 35 Withers M, Kharazmi N, Lim E. Traditional beliefs and practices in pregnancy, childbirth and postpartum: a review of the evidence from Asian countries. Midwifery 2018; 56: 158-170
• 36 Kaeser L. Task force on research specific to pregnant women and lactating women. Accessed September 2018 at: https://www.nichd.nih.gov/sites/default/files/2018-09/PRGLAC_Report.pdf
• 37 Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med 2016; 13 (11) e1002160
• 38 Benevent J, Montastruc F, Damase-Michel C. The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opin Drug Saf 2017; 16 (10) 1181-1190
• 39 Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL. Prescription of drugs during pregnancy in France. Lancet 2000; 356 (9243): 1735-1736
• 40 van Gelder MM, van Rooij IA, de Walle HE, Roeleveld N, Bakker MK. Maternal recall of prescription medication use during pregnancy using a paper-based questionnaire: a validation study in the Netherlands. Drug Saf 2013; 36 (01) 43-54
• 41 Alegría M, Chatterji P, Wells K. et al. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatr Serv 2008; 59 (11) 1264-1272
• 42 Yamamoto A, McCormick MC, Burris HH. Disparities in antidepressant use in pregnancy. J Perinatol 2015; 35 (04) 246-251